title: Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.
abstract: Detailed analysis of data from studies of recombinant antihemophilic factor produced using a plasma/albumin-free method (rAHF-PFM) in previously treated patients showed a substantial level of interpatient variation in pharmacokinetics (PKs), factor VIII dosing, and annualized bleed rate (ABR), suggesting that individual patient characteristics contributed to outcome. For example, plasma half-life (t1/2), recovery, and clearance appeared to differ between patients aged <6 years and 10-65 years. Prophylaxis resulted in lower ABRs than episodic treatment in both age groups; better adherence to the prophylactic regimen resulted in a lower ABR in patients aged 10-65 years. The weekly frequency of dosing and adherence to dosing were both significantly and inversely related to the rate of bleeding (young children, P<0.0001 for both all bleeds and joint bleeds; older patients, P<0.0001 for all bleeds and P<0.05 for joint bleeds), as was adherence to dosing frequency (P<0.0001 for all comparisons). A post-marketing randomized study of prophylaxis demonstrated that a PK-guided dosing regimen, based on an individual patient's rAHF-PFM PK (infusion interval, estimated t1/2, and recovery), was as effective as standard prophylaxis and that both prophylactic regimens were superior to episodic treatment with respect to ABR and quality of life measures. Thus, compared with standard prophylaxis, the PK-guided regimen achieved comparable efficacy with fewer weekly infusions. A two-compartment population PK model describes the PK data across the entire age range and forms the basis for future PK-guided therapy with rAHF-PFM. The model confirmed a shorter t1/2 and faster clearance of rAHF-PFM in children <6 years of age versus patients ≥10 years and predicted similar PK parameters with either a full or reduced blood sampling schedule, offering the potential for the use of PK-guided, individualized treatment in the routine clinical care setting.
authors.affiliation: Malmö Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden.
authors.forename: Erik
authors.initials: E
authors.lastname: Berntorp
authors.affiliation: Baxter Healthcare Corporation, Westlake Village, CA, USA.
authors.forename: Gerald
authors.initials: G
authors.lastname: Spotts
authors.affiliation: Baxter Healthcare Corporation, Westlake Village, CA, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Patrone
authors.affiliation: Baxter Healthcare Corporation, Westlake Village, CA, USA.
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Ewenstein
keywords: ADVATE; FVIII; individualized; pharmacokinetics; prophylaxis; rAHF-PFM
references.citation: N Engl J Med. 2007 Aug 9;357(6):535-44
references.pmid: 17687129
references.citation: Haemophilia. 2003 May;9 Suppl 1:94-9; discussion 100
references.pmid: 12709044
references.citation: J Thromb Haemost. 2010 Jan;8(1):83-9
references.pmid: 19817995
references.citation: Haematologica. 2005 Apr;90(4):494-8
references.pmid: 15820945
references.citation: Br J Haematol. 2005 Jul;130(1):107-12
references.pmid: 15982352
references.citation: Haemophilia. 2010 Nov;16(6):866-77
references.pmid: 20579113
references.citation: Haemophilia. 2007 Sep;13 Suppl 2:10-5
references.pmid: 17685918
references.citation: Arch Intern Med. 1970 Jun;125(6):1004-9
references.pmid: 4951928
references.citation: Haemophilia. 2011 May;17(3):412-21
references.pmid: 21332888
references.citation: Haemophilia. 2001 Sep;7(5):446-52
references.pmid: 11554930
references.citation: J Thromb Haemost. 2012 Mar;10(3):359-67
references.pmid: 22212248
references.citation: Br J Haematol. 1995 Oct;91(2):474-6
references.pmid: 8547097
references.citation: Haemophilia. 2004 Nov;10(6):689-97
references.pmid: 15569163
references.citation: Haemophilia. 2007 Sep;13(5):473-9
references.pmid: 17880432
references.citation: Scand J Haematol Suppl. 1977;30:79-80
references.pmid: 327532
references.citation: Eur J Clin Pharmacol. 2009 Oct;65(10):989-98
references.pmid: 19557401
references.citation: Blood. 2002 Apr 1;99(7):2337-41
references.pmid: 11895765
references.citation: J Intern Med. 1992 Jul;232(1):25-32
references.pmid: 1640190
references.citation: Haemophilia. 2011 Jan;17(1):e239-40
references.pmid: 20731725
references.citation: Acta Paediatr Scand. 1981 Jul;70(4):565-70
references.pmid: 6797235
references.citation: J Thromb Haemost. 2009 Mar;7(3):413-20
references.pmid: 19143924
references.citation: Haemophilia. 2005 Nov;11(6):571-82
references.pmid: 16236106
references.citation: Am J Hematol. 1998 Dec;59(4):288-94
references.pmid: 9840909
references.citation: Acta Paediatr Scand. 1976 Mar;65(2):129-35
references.pmid: 1258628
references.citation: Haemophilia. 2011 Jan;17(1):2-10
references.pmid: 20731726
references.citation: Haemophilia. 2002 Mar;8(2):112-20
references.pmid: 11952846
references.citation: Haemophilia. 2005 Mar;11(2):84-91
references.pmid: 15810908
references.citation: Ther Drug Monit. 2007 Feb;29(1):20-6
references.pmid: 17304146
references.citation: J Thromb Haemost. 2010 Feb;8(2):269-75
references.pmid: 19943875
references.citation: Blood Transfus. 2012 Apr;10(2):123-4
references.pmid: 22337279
references.citation: Haemophilia. 2012 Nov;18(6):855-9
references.pmid: 22681244
references.citation: Haemophilia. 2010 Jul 1;16(4):597-605
references.pmid: 20148977
references.citation: Haemophilia. 2013 Jan;19(1):21-6
references.pmid: 22845803
references.citation: Eur J Haematol. 1993 Oct;51(4):247-52
references.pmid: 8243614
references.citation: Haemophilia. 2002 Nov;8(6):745-52
references.pmid: 12410642
references.citation: Thromb Haemost. 2012 Jun;107(6):1072-82
references.pmid: 22476554
references.citation: Haemophilia. 2012 Sep;18(5):760-5
references.pmid: 22548353
references.citation: Haemophilia. 2009 Sep;15(5):1014-21
references.pmid: 19493018
references.citation: Haemophilia. 2005 Mar;11(2):109-15
references.pmid: 15810912
references.citation: Ann Hematol. 2013 May;92(5):689-98
references.pmid: 23324986
references.citation: Haemophilia. 2004 Sep;10(5):428-37
references.pmid: 15357767
references.citation: J Thromb Haemost. 2008 Aug;6(8):1319-26
references.pmid: 18503631
references.citation: Haemophilia. 2003 May;9 Suppl 1:101-8; discussion 109-10
references.pmid: 12709045
references.citation: Haemophilia. 2002 Mar;8(2):98-103
references.pmid: 11952844
references.citation: Haemophilia. 2004 Mar;10 Suppl 1:26-33
references.pmid: 14987246
references.citation: Bibl Haematol. 1970;34:111-24
references.pmid: 5436339
references.citation: Blood. 2012 Jan 12;119(2):612-8
references.pmid: 22042695
references.citation: Haemophilia. 2011 May;17(3):433-8
references.pmid: 21299740
references.citation: Vasc Health Risk Manag. 2007;3(5):555-65
references.pmid: 18078007
references.citation: J Thromb Haemost. 2010 Apr;8(4):730-6
references.pmid: 20398185